The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Residents’ JournalFull Access

Highlights From the Residents’ Journal: June 2022

The AJP Residents’ Journal is a quarterly e-publication that serves as a forum for resident physicians and fellows to share ideas and experiences in training, clinical practice, research, and careers.

Ketamine for Adolescent Depression: An Overview and Considerations for Future Directions

Janet J. Baek, M.D., Earth Hasassri, M.D.

Ketamine has emerged as an increasingly utilized treatment option as augmentation for refractory depression for adults and is noted for its rapid antidepressant and antisuicidality effects, with a large effect size of 0.9, compared with placebo. Several international task forces have reviewed the evidence for efficacy and safety of ketamine and have provided recommendations for its use in clinical practice for adults but not for adolescents. Here we review the current literature on use of ketamine for adolescent depression.

Modafinil: A Review and Its Potential Use in the Treatment of Long COVID Fatigue and Neurocognitive Deficits

Andrew G. Pliszka, B.S.A.

Modafinil is a eugeroic agent approved for treating fatigue in narcolepsy and shift-work sleep disorder. It has been shown to have antioxidant effects preclinically and clinical efficacy in treating neurocognitive symptoms. This article describes findings from a literature review that focused on modafinil’s mechanisms of action and its possible role in treating the fatigue and neurocognitive deficits of long COVID.

Community Treatment Orders in Canada: A Historical Overview

Olivia Guerra, M.D., B.A.

In this article, the origin of community treatment orders in Canada following the era of deinstitutionalization is explored. The goal is not to argue either for or against but to help provide the reader with context, highlight both perspectives, and encourage thought. Ethical considerations in the COVID-19 pandemic are used to highlight areas of controversy and encourage further discussion and research interest regarding community care for people with SMI.

ALSO IN THIS ISSUE

Recurrent Catatonia Pre- and Postorthotopic Liver Transplant

Christopher Sikes-Keilp, M.D.

The Debate Over Sensory Processing Disorder

Aimee Le-Huynh McArthur, D.O., M.P.H.

American Journal of Psychiatry Residents’ Journal Editorial Board, 2022–2023

For the full articles and other features of the current issue, please visit https://ajp.psychiatryonline.org/toc/ajp-rj/17/4